Chemed (NYSE:CHE) Reaches New 52-Week High – Should You Buy?

Chemed Corporation (NYSE:CHE)’s share price reached a new 52-week high during trading on Thursday . The stock traded as high as $485.98 and last traded at $482.92, with a volume of 11472 shares traded. The stock had previously closed at $480.87.

Analyst Upgrades and Downgrades

CHE has been the topic of a number of research reports. Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Royal Bank Of Canada upped their price target on shares of Chemed from $422.00 to $436.00 and gave the company a “sector perform” rating in a report on Monday, April 27th. Weiss Ratings upgraded shares of Chemed from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. Finally, Wall Street Zen cut shares of Chemed from a “buy” rating to a “hold” rating in a research note on Monday, June 8th. Two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $501.50.

Chemed Stock Performance

The company has a quick ratio of 0.83, a current ratio of 0.85 and a debt-to-equity ratio of 0.11. The stock has a fifty day moving average price of $431.51 and a two-hundred day moving average price of $425.98. The company has a market capitalization of $6.44 billion, a price-to-earnings ratio of 26.47, a PEG ratio of 1.75 and a beta of 0.52.

Chemed (NYSE:CHE) last posted its quarterly earnings data on Thursday, April 23rd. The company reported $5.65 EPS for the quarter, beating analysts’ consensus estimates of $5.30 by $0.35. Chemed had a return on equity of 27.18% and a net margin of 10.23%.The business had revenue of $657.51 million for the quarter, compared to analyst estimates of $659.22 million. During the same quarter last year, the company earned $5.63 earnings per share. The business’s revenue for the quarter was up 1.6% compared to the same quarter last year. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. As a group, analysts forecast that Chemed Corporation will post 22.3 EPS for the current fiscal year.

Chemed Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Thursday, May 28th were given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend was Thursday, May 28th. Chemed’s payout ratio is currently 13.08%.

Insider Activity at Chemed

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the business’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $421.13, for a total value of $842,260.00. Following the completion of the transaction, the chief executive officer directly owned 90,219 shares in the company, valued at approximately $37,993,927.47. The trade was a 2.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Andrea R. Lindell sold 1,347 shares of the stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $447.33, for a total value of $602,553.51. Following the transaction, the director directly owned 4,578 shares in the company, valued at approximately $2,047,876.74. This represents a 22.73% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 3.33% of the company’s stock.

Institutional Investors Weigh In On Chemed

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Maripau Wealth Management LLC lifted its position in Chemed by 5.4% during the first quarter. Maripau Wealth Management LLC now owns 970 shares of the company’s stock worth $366,000 after buying an additional 50 shares during the period. Segall Bryant & Hamill LLC purchased a new stake in Chemed in the 1st quarter valued at about $2,293,000. Cim LLC grew its holdings in Chemed by 1.6% in the 1st quarter. Cim LLC now owns 2,325 shares of the company’s stock valued at $878,000 after buying an additional 37 shares during the period. Amundi increased its stake in shares of Chemed by 6,982.7% during the 1st quarter. Amundi now owns 35,555 shares of the company’s stock valued at $13,431,000 after acquiring an additional 35,053 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Chemed by 9.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 406 shares of the company’s stock valued at $153,000 after acquiring an additional 35 shares during the last quarter. Hedge funds and other institutional investors own 95.85% of the company’s stock.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.